Saint Louis, Missouri 63110

  • Preterm Birth

Purpose:

Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk preterm birth, cesarean section, and maternal critical care. This study will examine the factors that impede testing for SARS-CoV-2 (the causative virus among pregnant women), help determine optimal testing strategies by evaluating the necessity of testing for asymptomatic disease in pregnancy, inform prenatal care plans by assessing the full impact of infection, and contribute to a provider's ability to counsel women and create prenatal care plans if they are pregnant or considering pregnancy.


Study summary:

Pregnant women are a vulnerable and high-risk population, as COVID-19 is associated with an increased risk of preterm birth, cesarean section, and maternal intensive care. The objectives of this study are to: (a) evaluate the full impact of SARS-CoV-2 in pregnancy to inform testing strategies, (b) examine the factors that impede testing during pregnancy, and (c) use study data to devise implementation strategies that improve SARS-CoV-2 testing in pregnancy and prenatal care during the pandemic. Investigators will prospectively enroll two cohorts of pregnant women: 1) exposed (SARS-CoV-2 positive), and 2) unexposed (SARS-CoV-2 negative as defined by antibody testing at the beginning of pregnancy, every trimester, and at delivery). Women who initially enroll as unexposed but later test positive for SARS-CoV-2 antibodies will cross over to the exposed cohort. In Aim 1, investigators will evaluate patients' and providers' perceptions of SARS-CoV-2 testing during pregnancy and the influence of COVID-19 on maternal care-seeking behavior and anxiety via surveys and semi-structured interviews. In Aim 2, investigators will determine the effect of SARS-CoV-2 infection during pregnancy on the risk of preterm birth and other adverse pregnancy outcomes in symptomatic and asymptomatic disease. It is hypothesized that SARS-CoV-2 infection will increase the risk of preterm birth by 12%. In Aim 3, investigators will estimate the risk of mother-to-fetus SARS-CoV-2 transmission and viral presence in umbilical cord blood, placenta, and amniotic fluid by assaying for viral RNA in the neonate, cord blood, and placenta. Collectively, Aims 1-3 will be interpreted by investigators, the Scientific Advisory Board and the Community Advisory Board who will apply data to devising targeted implementation strategies designed for rapid community dissemination to improve testing and prenatal care.


Criteria:

Inclusion Criteria for exposed (SARS-CoV-2 positive) cohort: - Viable intrauterine pregnancy - Seroconversion or SARS-CoV-2 IgG antibodies or positive RT-PCR for SARS-CoV-2 during current pregnancy Exclusion Criteria for exposed (SARS-CoV-2 positive) cohort: - No viable intrauterine pregnancy - No history of SARS-CoV-2 infection during pregnancy Inclusion Criteria for unexposed (SARS-CoV-2 negative) cohort: - Viable intrauterine pregnancy - No history of SARS-CoV-2 infection prior to pregnancy Exclusion Criteria for unexposed (SARS-CoV-2 negative) cohort: - No viable intrauterine pregnancy - Detection of SARS-CoV-2 IgG antibodies at enrollment


NCT ID:

NCT04718220


Primary Contact:

Principal Investigator
Megan E Foeller, MD
Washington University School of Medicine

Megan E Foeller, MD
Phone: 314-747-1380
Email: mfoeller@wustl.edu


Backup Contact:

Email: imysorekar@wustl.edu
Indira Mysorekar, PhD


Location Contact:

Saint Louis, Missouri 63110
United States

Megan E Foeller, MD
Email: mfoeller@wustl.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 22, 2021

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.